Allianz SE Invests $151,000 in Moderna, Inc. (NASDAQ:MRNA)

Allianz SE purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,842 shares of the company’s stock, valued at approximately $151,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. abrdn plc grew its stake in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after acquiring an additional 69,360 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in Moderna by 30.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after purchasing an additional 23,881 shares during the last quarter. Spire Wealth Management grew its stake in Moderna by 2,150.4% during the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock valued at $966,000 after purchasing an additional 22,192 shares in the last quarter. Geode Capital Management LLC increased its holdings in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its position in shares of Moderna by 4,418.9% in the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock valued at $6,127,000 after purchasing an additional 144,099 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Evercore ISI set a $50.00 price target on shares of Moderna in a research report on Friday, February 14th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price target for the company. Finally, UBS Group lowered their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Trading Down 8.9 %

Shares of NASDAQ MRNA opened at $28.35 on Tuesday. Moderna, Inc. has a 12-month low of $26.80 and a 12-month high of $170.47. The company has a market cap of $10.96 billion, a PE ratio of -3.05 and a beta of 1.86. The stock has a 50 day simple moving average of $34.60 and a 200-day simple moving average of $43.84.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.